MARC

LEADER 00000nab a2200000uu 4500
001 3271046339
003 UK-CbPIL
022 |a 2077-0383 
024 7 |a 10.3390/jcm14217575  |2 doi 
035 |a 3271046339 
045 2 |b d20250101  |b d20251231 
100 1 |a Araujo-Castro, Marta  |u Endocrinology & Nutrition Department, Hospital Universitario Ramón y Cajal & Instituto de Investigación Biomédica Ramón y Cajal (IRYCIS), Colmenar Viejo Street km 9, 28034 Madrid, Spain 
245 1 |a Real-World Data on the Efficacy and Safety of Osilodrostat in Patients with Cushing’s Disease in Spain 
260 |b MDPI AG  |c 2025 
513 |a Journal Article 
520 3 |a Objective: To evaluate the efficacy and safety of osilodrostat in patients with Cushing’s disease (CD). Methods: A retrospective, multicenter, real-world study of patients with CD. The main efficacy endpoint was the proportion of patients who were complete responders (urinary free cortisol [UFC] < the upper limit of normal and/or with adrenal insufficiency development). Results: Thirty-seven CD patients were enrolled. There were 33 patients who initially received osilodrostat in monotherapy and 4 in combination. However, 3 patients of the monotherapy group were switched to combination therapy. The median duration of osilodrostat treatment was 5 months (range 1–93). All the patients were classified as responders: 33 (89.2%) had complete response and 4 partial response. A positive correlation was detected between the percentage of UFC decrease and the maximum (r = 0.481, p = 0.006) and the maintenance doses (r = 0.440, p = 0.011). The initial doses of osilodrostat were a predictor of complete response (vs. partial) (Odds ratio [OR] 2.82, p = 0.030). The median time to UFC normalization in the group of complete responders was 4 weeks (range 1–20) and UFC normalized before or at month 1 in 67% (n = 20/30) of the patients. Osilodrostat led to a significant decrease in systolic and diastolic blood pressure in parallel with a reduction of antihypertensive medications. Conclusions: Osilodrostat leads to a complete UFC normalization in up to 90% of the patients with CD, in parallel with an improvement in the cardiometabolic profile. A proper titration of osilodrostat is important to achieve a complete response since a positive correlation between the doses and the UFC reduction was observed. 
651 4 |a Spain 
653 |a Patients 
653 |a Variables 
653 |a Quality of life 
653 |a Combination therapy 
653 |a Hormones 
653 |a Surgery 
653 |a Sinuses 
653 |a Drug dosages 
653 |a Statistical analysis 
700 1 |a García-Centeno Rogelio  |u Endocrinology &amp;amp; Nutrition Department, Hospital Universitario Gregorio Marañón, 28007 Madrid, Spain 
700 1 |a González, Laura  |u Endocrinology &amp;amp; Nutrition Department, Hospital Universitario Gregorio Marañón, 28007 Madrid, Spain 
700 1 |a Hanzu, Felicia A  |u Endocrinology &amp;amp; Nutrition Department, Hospital Clinic de Barcelona, 08036 Barcelona, Spain 
700 1 |a Orois Aida  |u Endocrinology &amp;amp; Nutrition Department, Hospital Clinic de Barcelona, 08036 Barcelona, Spain 
700 1 |a Camara, Rosa  |u Endocrinology &amp;amp; Nutrition Department, Hospital La Fe, 46600 Valencia, Spain 
700 1 |a García María Dolores Ollero  |u Endocrinology &amp;amp; Nutrition Department, Hospital Universitario Navarra, 31008 Pamplona, Spain 
700 1 |a Echarri Ana Irigaray  |u Endocrinology &amp;amp; Nutrition Department, Hospital Universitario Navarra, 31008 Pamplona, Spain 
700 1 |a Gracia Gimeno Paola  |u Endocrinology &amp;amp; Nutrition Department, Hospital Universitario Royo Villanova, 50015 Zaragoza, Spain 
700 1 |a Pascual-Corrales Eider  |u Endocrinology &amp;amp; Nutrition Department, Hospital Universitario Ramón y Cajal &amp;amp; Instituto de Investigación Biomédica Ramón y Cajal (IRYCIS), Colmenar Viejo Street km 9, 28034 Madrid, Spain 
700 1 |a Biagetti Betina  |u Endocrinology &amp;amp; Nutrition Department, Hospital Universitario Vall de Hebrón &amp;amp; CIBERER Group 747, 08035 Barcelona, Spain 
700 1 |a Cardona Andrés  |u Endocrinology &amp;amp; Nutrition Department, Hospital Universitario Vall de Hebrón &amp;amp; CIBERER Group 747, 08035 Barcelona, Spain 
700 1 |a González Molero Inmaculada  |u Endocrinology &amp;amp; Nutrition Department, Hospital Regional Universitario de Málaga, 29010 Málaga, Spain 
700 1 |a Simo-Servat Andreu  |u Endocrinology &amp;amp; Nutrition Department, Hospital Regional Universitario de Terrasa, 08227 Barcelona, Spain 
700 1 |a Guerrero Pérez Fernando  |u &lt;label&gt;10&lt;/label&gt;Endocrinology &amp;amp; Nutrition Department, Hospital Universitario de Bellvitge, L’Hospitalet de Llobregat, 08907 Cataluña, Spain 
700 1 |a Villar-Taibo Rocío  |u &lt;label&gt;11&lt;/label&gt;Endocrinology &amp;amp; Nutrition Department, Hospital Universitario de Santiago de Compostela, 15706 Galicia, Spain 
700 1 |a Bernabéu Ignacio  |u &lt;label&gt;11&lt;/label&gt;Endocrinology &amp;amp; Nutrition Department, Hospital Universitario de Santiago de Compostela, 15706 Galicia, Spain 
700 1 |a Fajardo-Montañana Carmen  |u &lt;label&gt;12&lt;/label&gt;Endocrinology &amp;amp; Nutrition Department, Hospital Universitario La Ribera, 46600 Valencia, Spain 
700 1 |a Novo-Rodríguez, Cristina  |u &lt;label&gt;13&lt;/label&gt;Endocrinology &amp;amp; Nutrition Department, Hospital Universitario Virgen de las Nieves, 18014 Granada, Spain 
700 1 |a Tenorio, Jimenéz Carmen  |u &lt;label&gt;13&lt;/label&gt;Endocrinology &amp;amp; Nutrition Department, Hospital Universitario Virgen de las Nieves, 18014 Granada, Spain 
700 1 |a Calatayud María  |u &lt;label&gt;14&lt;/label&gt;Endocrinology &amp;amp; Nutrition Department, Hospital Universitario 12 de Octubre, 28041 Madrid, Spain 
700 1 |a Moure Rodríguez María Dolores  |u &lt;label&gt;15&lt;/label&gt;Endocrinology &amp;amp; Nutrition Department, Hospital Universitario de Cruces, 48903 Bilbao, Spain 
700 1 |a Cordido Fernando  |u &lt;label&gt;16&lt;/label&gt;Endocrinology &amp;amp; Nutrition Department, Hospital Universitario A Coruña &amp;amp; Universidad de A Coruña, 15006 A Coruña, Spain 
700 1 |a Castro, Ana  |u &lt;label&gt;17&lt;/label&gt;Endocrinology &amp;amp; Nutrition Department, Hospital Universitario Toledo, 45007 Toledo, Spain 
700 1 |a Valero Lucía Manzano  |u &lt;label&gt;17&lt;/label&gt;Endocrinology &amp;amp; Nutrition Department, Hospital Universitario Toledo, 45007 Toledo, Spain 
700 1 |a Paja Fano Miguel  |u &lt;label&gt;18&lt;/label&gt;Endocrinology &amp;amp; Nutrition Department, OSI Bilbao-Basurto, Hospital Universitario de Basurto, 48013 Bilbao, Spain 
700 1 |a Goi Jessica  |u Endocrinology &amp;amp; Nutrition Department, Hospital Universitario Ramón y Cajal &amp;amp; Instituto de Investigación Biomédica Ramón y Cajal (IRYCIS), Colmenar Viejo Street km 9, 28034 Madrid, Spain 
700 1 |a Aulinas, Anna  |u &lt;label&gt;20&lt;/label&gt;Endocrinology &amp;amp; Nutrition Department, Hospital de la Santa Creu i Sant Pau, IR-SANT PAU, CIBERER U747 (ISCIII), 08025 Barcelona, Spain 
700 1 |a Abellán Pablo  |u &lt;label&gt;21&lt;/label&gt;Endocrinology &amp;amp; Nutrition Department, Hospital Universitario de Valencia, 46010 Valencia, Spain 
700 1 |a Iglesias, Pedro  |u &lt;label&gt;22&lt;/label&gt;Endocrinology &amp;amp; Nutrition Department, Hospital Universitario Puerta de Hierro, 28222 Madrid, Spain 
700 1 |a Soto-Moreno, Alfonso  |u &lt;label&gt;23&lt;/label&gt;Unidad de Gestión de Endocrinología y Nutrición, Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, 14004 Córdoba, Spain 
773 0 |t Journal of Clinical Medicine  |g vol. 14, no. 21 (2025), p. 7575-7588 
786 0 |d ProQuest  |t Health & Medical Collection 
856 4 1 |3 Citation/Abstract  |u https://www.proquest.com/docview/3271046339/abstract/embedded/6A8EOT78XXH2IG52?source=fedsrch 
856 4 0 |3 Full Text + Graphics  |u https://www.proquest.com/docview/3271046339/fulltextwithgraphics/embedded/6A8EOT78XXH2IG52?source=fedsrch 
856 4 0 |3 Full Text - PDF  |u https://www.proquest.com/docview/3271046339/fulltextPDF/embedded/6A8EOT78XXH2IG52?source=fedsrch